TScan Therapeutics Inc — Quarterly Financial Statistics (NASDAQ:TCRX) | MetaTrader

Open full chart

Financials

Overview Estratto Conto Statistics Dividends

Quarterly Annual

Cash from operating activities 27.92 M27.41 M37.59 M33.27 M32.46 M 130.73 M Cash from investing activities 77.46 M-27.29 M13.53 M48.44 M32.58 M 67.25 M Cash from financing activities 1.23 M45.69 M525 K-116 K0 46.1 M Free cash flow 26.55 M26.52 M36.05 M31.99 M31.04 M 125.61 M

Notizie

TScan completa l’arruolamento nella coorte dello studio, riceve l’autorizzazione FDA

TScan completes enrollment in trial cohort, receives FDA clearance

Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates

Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates

Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?

Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates

Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)

Tscan Therapeutics mantiene rating Neutrale da BTIG dopo evento ASH

Tscan Therapeutics stock holds Neutral rating at BTIG after ASH event

TScan to host KOL event discussing updated ALLOHA trial data

Morgan Stanley declassa le azioni di Tscan Therapeutics per ritardi nei trial

Morgan Stanley downgrades Tscan Therapeutics stock on delayed trials